APLS Q3 2022 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+290.4% YoY

Gross Profit

$21M93.7% margin

Operating Income

-$153M-693.4% margin

Net Income

-$191M-867.2% margin

EPS (Diluted)

$-1.75

QoQ Revenue Growth

+35.1%

Cash Flow

Operating Cash Flow

-$154M

Free Cash Flow

-$155M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$873M

Total Liabilities

$565M

Stockholders' Equity

$307M

Cash & Equivalents

$584M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$6M	+290.4%
Gross Profit	$21M	$6M	+275.8%
Operating Income	-$153M	-$128M	-19.5%
Net Income	-$191M	-$196M	+2.2%

Revenue Segments

Product

$18M80%

Licensing And Other Revenue

$4M20%